<code id='1E0CF848E5'></code><style id='1E0CF848E5'></style>
    • <acronym id='1E0CF848E5'></acronym>
      <center id='1E0CF848E5'><center id='1E0CF848E5'><tfoot id='1E0CF848E5'></tfoot></center><abbr id='1E0CF848E5'><dir id='1E0CF848E5'><tfoot id='1E0CF848E5'></tfoot><noframes id='1E0CF848E5'>

    • <optgroup id='1E0CF848E5'><strike id='1E0CF848E5'><sup id='1E0CF848E5'></sup></strike><code id='1E0CF848E5'></code></optgroup>
        1. <b id='1E0CF848E5'><label id='1E0CF848E5'><select id='1E0CF848E5'><dt id='1E0CF848E5'><span id='1E0CF848E5'></span></dt></select></label></b><u id='1E0CF848E5'></u>
          <i id='1E0CF848E5'><strike id='1E0CF848E5'><tt id='1E0CF848E5'><pre id='1E0CF848E5'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:1
          Primary care exam 01
          ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and Medtronic have run studies that showed renal denervation leads to a modest decrease in blood pressure. Adam Berry/Getty Images

          The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy.

          Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome. The therapy, which is meant to be a one-time procedure, is administered via a catheter. Electrodes on the catheter then emit radiofrequency or ultrasound energy to block nerve signals from the kidneys that increase blood pressure.

          advertisement

          The therapy, a simple procedure to reduce the blood pressure of millions of Americans, was once seen as a boon for cardiologists and device makers. But a large-scale clinical trial from Medtronic in 2014 called renal denervation’s efficacy into question, as it did not significantly reduce blood pressure compared to placebo treatments.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          An Ebola outbreak presents a new mystery involving children
          An Ebola outbreak presents a new mystery involving children

          YoungCongolesegirlslookataposterexplainingthesymptomsofEbola.JOHNWESSELS/AFP/GettyImagesEpidemiologi

          read more
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more

          Wegovy cuts risk of cardiovascular events by 20%, study finds

          AdobeNovoNordisk’sobesitydrugWegovycuttheriskofmajorheartcomplicationsby20%inacloselywatchedtrial,re